摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(±)-trans-4-[2-[2-chloro-4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]phenyl]cyclopropyl]benzoic acid | 1268244-87-6

中文名称
——
中文别名
——
英文名称
(±)-trans-4-[2-[2-chloro-4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]phenyl]cyclopropyl]benzoic acid
英文别名
4-((1R,2R)-2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isooxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid;4-((1R,2R)-2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid;PX20606 trans racemate;4-[(1R,2R)-2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]benzoic acid
(±)-trans-4-[2-[2-chloro-4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]phenyl]cyclopropyl]benzoic acid化学式
CAS
1268244-87-6
化学式
C29H22Cl3NO4
mdl
——
分子量
554.857
InChiKey
XBUXXJUEBFDQHD-SFTDATJTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    690.1±55.0 °C(Predicted)
  • 密度:
    1.444±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    7.6
  • 重原子数:
    37
  • 可旋转键数:
    8
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    72.6
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • FXR AGONISTS AND METHODS FOR MAKING AND USING
    申请人:Salk Institute for Biological Studies
    公开号:US20160376279A1
    公开(公告)日:2016-12-29
    Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
  • Isoxazole Analogs as FXR Agonists and Methods of Use Thereof
    申请人:Enanta Pharmaceuticals, Inc.
    公开号:US20170334893A1
    公开(公告)日:2017-11-23
    The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
  • INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS
    申请人:Salk Institute for Biological Studies
    公开号:US20180000768A1
    公开(公告)日:2018-01-04
    Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (LADA) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid X receptor (FXR) agonist compounds, thereby activating FXR receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (LADA) in the subject.
  • Medicine Obtained by Combining FXR Agonist and ARB
    申请人:SUMITOMO DAINIPPON PHARMA CO., LTD.
    公开号:US20190247404A1
    公开(公告)日:2019-08-15
    The present invention provides an NASH therapeutic agent including: an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof; and an ARB or a pharmaceutically acceptable salt thereof.
  • [EN] FXR AGONISTS AND METHODS FOR MAKING AND USING<br/>[FR] AGONISTES FXR ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
    申请人:SALK INST FOR BIOLOGICAL STUDI
    公开号:WO2015138986A1
    公开(公告)日:2015-09-17
    Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
查看更多

同类化合物

(E,Z)-他莫昔芬N-β-D-葡糖醛酸 (E/Z)-他莫昔芬-d5 (4S,5R)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R,4''R,5S,5''S)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (1R,2R)-2-(二苯基膦基)-1,2-二苯基乙胺 鼓槌石斛素 高黄绿酸 顺式白藜芦醇三甲醚 顺式白藜芦醇 顺式己烯雌酚 顺式-桑皮苷A 顺式-曲札芪苷 顺式-二苯乙烯 顺式-beta-羟基他莫昔芬 顺式-a-羟基他莫昔芬 顺式-3,4',5-三甲氧基-3'-羟基二苯乙烯 顺式-1,2-二苯基环丁烷 顺-均二苯乙烯硼酸二乙醇胺酯 顺-4-硝基二苯乙烯 顺-1-异丙基-2,3-二苯基氮丙啶 阿非昔芬 阿里可拉唑 阿那曲唑二聚体 阿托伐他汀环氧四氢呋喃 阿托伐他汀环氧乙烷杂质 阿托伐他汀环(氟苯基)钠盐杂质 阿托伐他汀环(氟苯基)烯丙基酯 阿托伐他汀杂质D 阿托伐他汀杂质94 阿托伐他汀内酰胺钠盐杂质 阿托伐他汀中间体M4 阿奈库碘铵 银松素 铒(III) 离子载体 I 钾钠2,2'-[(E)-1,2-乙烯二基]二[5-({4-苯胺基-6-[(2-羟基乙基)氨基]-1,3,5-三嗪-2-基}氨基)苯磺酸酯](1:1:1) 钠{4-[氧代(苯基)乙酰基]苯基}甲烷磺酸酯 钠;[2-甲氧基-5-[2-(3,4,5-三甲氧基苯基)乙基]苯基]硫酸盐 钠4-氨基二苯乙烯-2-磺酸酯 钠3-(4-甲氧基苯基)-2-苯基丙烯酸酯 重氮基乙酸胆酯酯 醋酸(R)-(+)-2-羟基-1,2,2-三苯乙酯 酸性绿16 邻氯苯基苄基酮 那碎因盐酸盐 那碎因[鹼] 达格列净杂质54 辛那马维林 赤藓型-1,2-联苯-2-(丙胺)乙醇 赤松素 败脂酸,丁基丙-2-烯酸酯,甲基2-甲基丙-2-烯酸酯,2-甲基丙-2-烯酸